XML 66 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 28 Months Ended 37 Months Ended 59 Months Ended 68 Months Ended
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Item
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
License And Collaboration Agreements [Line Items]                              
Revenue recognized related to upfront and milestone payments                 $ 5,691,000 $ 1,131,000          
Licenses revenue             $ 156,499,000 $ 112,408,000 446,809,000 286,478,000          
Deferred revenue             18,905,000 19,579,000 18,905,000 19,579,000 $ 20,710,000 $ 20,846,000 $ 18,905,000 $ 20,846,000 $ 18,905,000
Product Revenue, Net                              
License And Collaboration Agreements [Line Items]                              
Licenses revenue             155,190,000 $ 112,250,000 $ 441,118,000 285,347,000          
Mochida | In-licenses                              
License And Collaboration Agreements [Line Items]                              
Milestones payment   $ 1,000,000.0                          
Mochida | In-licenses | Research and Development Expense                              
License And Collaboration Agreements [Line Items]                              
Upfront payment                     $ 2,700,000        
Eddingpharm | Out-licenses                              
License And Collaboration Agreements [Line Items]                              
Non-refundable up-front received           $ 15,000,000.0                  
Number of indications of the regulatory milestone events relating to the submission and approval | Item                 3            
Amounts to be received upon achievement of the regulatory milestone events                 $ 33,000,000.0            
Sales-based milestone event payment                 120,000,000.0            
Revenue recognized related to upfront and milestone payments                 2,200,000 200,000          
Deferred revenue             10,800,000   10,800,000     13,000,000.0 10,800,000 13,000,000.0 10,800,000
Eddingpharm | Out-licenses | Licensing Revenue                              
License And Collaboration Agreements [Line Items]                              
Licenses revenue                           3,000,000.0 5,200,000
Eddingpharm | Out-licenses | Maximum                              
License And Collaboration Agreements [Line Items]                              
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                 153,000,000.0            
Amounts to be received upon achievement of the regulatory milestone events                 15,000,000.0            
Sales-based milestone event payment                 50,000,000.0            
Eddingpharm | Out-licenses | Minimum                              
License And Collaboration Agreements [Line Items]                              
Amounts to be received upon achievement of the regulatory milestone events                 2,000,000.0            
Sales-based milestone event payment                 5,000,000.0            
Eddingpharm | Out-licenses | Clinical Trial Application                              
License And Collaboration Agreements [Line Items]                              
Non-refundable milestone payment         $ 1,000,000.0                    
Biologix FZCo | Out-licenses                              
License And Collaboration Agreements [Line Items]                              
Revenue recognition period of non-refundable up-front payment         10 years                    
Biologix FZCo | Out-licenses | Product Revenue, Net                              
License And Collaboration Agreements [Line Items]                              
Licenses revenue             500,000   500,000 300,000          
HLS | Out-licenses                              
License And Collaboration Agreements [Line Items]                              
Non-refundable up-front received       $ 5,000,000.0                      
Non-refundable milestone payment $ 2,500,000 $ 3,800,000 $ 2,500,000 $ 2,500,000                      
Revenue recognized related to upfront and milestone payments                 3,500,000 900,000          
Deferred revenue             $ 7,400,000   7,400,000     7,100,000 7,400,000 $ 7,100,000 $ 7,400,000
Non-refundable up-front received period       6 months                      
Non-refundable milestone payment received       $ 3,800,000                      
HLS | Out-licenses | Licensing Revenue                              
License And Collaboration Agreements [Line Items]                              
Licenses revenue                       $ 2,900,000 $ 6,400,000    
HLS | Out-licenses | Product Revenue, Net                              
License And Collaboration Agreements [Line Items]                              
Licenses revenue                 $ 8,500,000 $ 0          
HLS | Out-licenses | Maximum                              
License And Collaboration Agreements [Line Items]                              
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone       $ 50,000,000.0